NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, dose-escalation phase I trial is to evaluate the safety,
tolerability and pharmacokinetic profiles and to assess the efficacy of NOV120401 (CKD-516
Tablet), a novel vascular disrupting agent, in patients with advanced refractory solid
tumors.